Baseline characteristics of the study population (n=8636)
| 60–69 Years | 70–79 Years | ≥80 Years | |
|---|---|---|---|
| n=4128 | n=3530 | n=978 | |
| Men, n (%) | 2011 (48.7) | 1505 (42.6) | 357 (36.5) |
| Age, mean±SD (years) | 64.7±2.8 | 74.0±2.8 | 83.1±3.3 |
| Hypertension, n (%) | 1855 (44.9) | 1738 (49.2) | 451 (46.1) |
| Systolic blood pressure, mean±SD (mm Hg) | 134±14 | 136±14 | 135±15 |
| Systolic blood pressure categories, n (%), mm Hg | |||
| <120 | 394 (9.5) | 264 (7.5) | 70 (7.2) |
| 120–129 | 1001 (24.2) | 779 (22.1) | 240 (24.5) |
| 130–139 | 1232 (29.8) | 1033 (29.3) | 287 (29.3) |
| 140–149 | 951 (23.0) | 872 (24.7) | 236 (24.1) |
| ≥150 | 550 (13.3) | 582 (16.5) | 145 (14.8) |
| Diastolic blood pressure (mm Hg), mean±SD | 80±8 | 78±7 | 76±7 |
| Diastolic blood pressure categories, n (%), mm Hg | |||
| <70 | 143 (3.5) | 185 (5.2) | 90 (9.2) |
| 70–79 | 1183 (28.7) | 1248 (35.4) | 394 (40.3) |
| 80–89 | 2240 (54.3) | 1795 (50.8) | 445 (45.5) |
| ≥90 | 562 (13.6) | 302 (8.6) | 49 (5.0) |
| Pulse pressure, mean±SD (mm Hg) | 54±11 | 57±12 | 59±13 |
| Pulse pressure, n (%), mm Hg | |||
| <50 | 1295 (31.4) | 776 (22.0) | 194 (19.8) |
| 50–59 | 1495 (36.2) | 1205 (34.1) | 308 (31.5) |
| 60–69 | 940 (22.8) | 972 (27.5) | 282 (28.8) |
| ≥70 | 398 (9.6) | 577 (16.3) | 194 (19.8) |
| Baseline eGFR, mean±SD (mL/min/1.73 m2) | 68.8±13.8 | 63.2±14.7 | 55.4±15.3 |
| Baseline eGFR categories, n (%), mL/min/1.73 m2 | |||
| ≥60 | 3167 (76.7) | 2097 (59.4) | 356 (36.4) |
| 45–59 | 850 (20.6) | 1119 (31.7) | 377 (38.5) |
| 30–44 | 97 (2.3) | 268 (7.6) | 204 (20.9) |
| <30 | 14 (0.3) | 46 (1.3) | 41 (4.2) |
| Charlson comorbidity index, median (IQR), n (%) | 3 (2–4) | 4 (3–5) | 6 (5–7) |
| Diabetes | 859 (20.8) | 800 (22.7) | 220 (22.5) |
| Myocardial infarction | 231 (5.6) | 237 (6.7) | 80 (8.2) |
| Heart failure | 135 (3.3) | 313 (8.9) | 201 (20.6) |
| CVA or TIA | 318 (7.7) | 556 (15.8) | 229 (23.4) |
| Peripheral arterial illness | 322 (7.8) | 404 (11.4) | 118 (12.1) |
| Chronic pulmonary disease | 144 (3.5) | 146 (4.1) | 36 (3.7) |
| History of peptic ulcer disease | 381 (9.2) | 393 (11.1) | 108 (11.0) |
| Dementia | 49 (1.2) | 213 (6.0) | 87 (8.9) |
| Liver disease | 172 (4.2) | 123 (3.5) | 26 (2.7) |
| Hemiplegia | 40 (1.0) | 60 (1.7) | 20 (2.0) |
| History of cancer | 523 (12.7) | 557 (15.8) | 148 (15.1) |
| Leukemia | 19 (0.5) | 24 (0.7) | 6 (0.6) |
| Lymphoma | 20 (0.5) | 27 (0.8) | 7 (0.7) |
| Cardiovascular medication, n (%) | 2061 (49.9) | 1925 (54.5) | 554 (56.6) |
| β-blockers | 1262 (30.6) | 1122 (31.8) | 247 (25.3) |
| ACE inhibitors | 490 (11.9) | 509 (14.4) | 150 (15.3) |
| Angiotensin receptor blocker | 362 (8.8) | 300 (8.5) | 79 (8.1) |
| Calcium antagonist | 463 (11.2) | 553 (15.7) | 167 (17.1) |
| Diuretic | 905 (21.9) | 964 (27.3) | 338 (34.6) |
CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; TIA, transient ischaemic attack.